Skip to main content
. 2021 Oct 19;35(3):272–280. doi: 10.1093/ajh/hpab168

Table 1.

Baseline characteristics of study population

No HF HFrEF HFpEF P value
n 106 30 18
Age [years] 64.0 ± 10.9 67.3 ± 11.2 66.4 ± 10.7 0.2937
Male sex 100 (94.34%) 30 (100.00%) 16 (88.89%) 0.2265
Race
 White 54 (50.94%) 12 (40.00%) 8 (44.44%) 0.5412
 African American 46 (43.40%) 18 (60.00%) 10 (55.56%) 0.2185
 Other 6 (5.66%) 0 (0.00%) 0 (0.00%) 0.2433
BMI [kg/m2] 29.0 ± 6.1 28.7 ± 4.2 33.9 ± 7.8 0.0056
Systolic blood pressure [mm Hg] 138 (130,156) 149 (131,169) 150 (142,160) 0.0819
Diastolic blood pressure [mm Hg] 87 (82,95) 89 (84,103) 92 (84,95) 0.1432
Hypertension 78 (74.29%) 23 (76.67%) 17 (94.44%) 0.1700
Coronary artery disease 27 (25.71%) 9 (30.00%) 8 (44.44%) 0.2646
COPD 10 (9.62%) 5 (16.67%) 4 (22.22%) 0.2438
eGFR [ml/min/1.73 m2] 86 (68,101) 79 (61,98) 85 (50,92) 0.4656
Diabetes mellitus 42 (40.00%) 11 (36.67%) 11 (64.71%) 0.1276
Current smoking 28 (27.72%) 6 (20.69%) 3 (16.67%) 0.5083
Medication use
 Beta blockers 50 (47.17%) 25 (86.21%) 13 (72.22%) 0.0003
 Aspirin 54 (50.94%) 20 (68.97%) 11 (61.11%) 0.1969
 ACE inhibitors or ARBs 53 (50.00%) 24 (82.76%) 15 (83.33%) 0.0006
 Furosemide 2 (1.90%) 18 (62.07%) 12 (66.67%) <0.0001
 Spironolactone 6 (5.66%) 7 (24.14%) 1 (5.56%) 0.0080
 Statins 75 (70.75%) 25 (86.21%) 12 (66.67%) 0.2003
 Long-acting nitrates 8 (7.55%) 2 (7.14%) 3 (16.67%) 0.4224
 Hydralazine 2 (1.89%) 1 (3.45%) 3 (16.67%) 0.0114
 Warfarin 8 (7.55%) 5 (17.24%) 0 (0.00%) 0.0979
 Calcium-channel blockers 30 (28.30%) 5 (17.24%) 8 (44.44%) 0.1304
 Thiazides 23 (21.90%) 3 (10.34%) 3 (16.67%) 0.3599

For continuous variables, values denote mean ± standard deviation (when normally distributed) or median (25th, 75th percentile) (otherwise). For discrete variables, values denote count (percentage). Systolic and diastolic blood pressures refer to the right-brachial blood pressures as obtained using the VaSera device. P values < 0.05 are printed in bold. Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.